Dermatology

A propensity-matched study shows dupilumab reduces gastrointestinal and endocrine IMID risk by 43-46% but raises psoriasis risk by 24%.

Lieberman, spoke at RAD 2026 about highlights from his session, ‘Connecting AD to Other Dermatologic Disorders and Related Comorbidities.'

RAD 2026 analyses reveal the impact of CHE on patients' lives, including its financial effects and influence on treatment decision-making.

Real-world data from the international TRACE study show 12 months of tralokinumab improved skin and quality-of-life outcomes.

DiRuggiero on PsO-LD, a heating pad for molluscum, and why psoriasis counseling must now include pulmonary risk.

This video feature highlights the views of dermatologists on prior authorization, step therapy, and issues related to these processes.

Dermatologists write up to 10% of US antibiotics. At SDPA 2026, Douglas DiRuggiero, PA-C, explains why that must change and what to use instead.

This discussion centers on patient empowerment, shared decision-making, and advancing equitable dermatologic care for those with skin of color.

Phase 3 VITESSE subgroup data show response rates of 46% to 48% in children with peanut allergy and concomitant asthma, atopic dermatitis, or food allergies, says David Fleischer, MD.

In her SDPA interview, Min discusses dermatology and rheumatology collaboration, exploring treatment options for connective tissue disease.

This SDPA interview highlights the connection between dermatology and rheumatology, noting diagnoses that can be challenging for rheumatologists.

This SDPA Summer Conference interview with Lisa Swanson, MD, highlights several notable treatment options for molluscum and hemangiomas.

At SDPA, Swanson highlighted a variety of key tips for clinicians, including strategies for treating hemangiomas and warts in children.

This Q&A interview highlights ways to counsel patients regarding the safety of various sunscreens, photoprotection, and UV radiation's impact on skin cancer.

This interview at the SDPA Summer Conference highlights the environment and climate change's impact on skin health and triggers of different conditions.

Stay updated with the latest healthcare breakthroughs, including data from ADA Scientific Sessions, a new CKM syndrome guideline, and more.

At the SDPA 2026 Summer Dermatology Conference, Mark Eliason, MD, and Mili Shum, MD, presented a joint session on treating chronic urticaria (CSU).

This SDPA interview with Steven Daveluy, MD, highlights integrative dermatology practices, acne strategies, and the value of supplements and dietary changes.

This discussion of integrative dermatology highlights ways to combine conventional medicine and complementary or alternative medicine.

In this SDPA Summer Dermatology Meeting interview, Zirwas speaks on treatment gaps for dermatologic conditions and off-label alternatives.

LATITUDE Atlas saw more than 35% of patients receiving zasocitinib 30 mg once daily reaching a PASI100 response at week 16, the primary endpoint.

This SDPA Summer 2026 talk highlights off-label treatment tips for dermatology clinicians in conditions such as alopecia areata, morphea, and different genital conditions.

This preview of the 2026 SDPA Summer Dermatology Conference highlights different sessions and interviews covered by the HCPLive team.

Eli Lilly announced FDA approval of a 250 mg every-8-week lebrikizumab maintenance regimen, supported by 32-week ADjoin extension data.

Natasha Mesinkovska, MD, PhD, speaks on the potential impact that an additional approved therapy like upadacitinib could have on younger patients with alopecia areata.